top of page

Revolutionizing the Treatment of Age‑Related Diseases

The global population is rapidly aging, leading to a growing incidence of age‑related diseases.

Obesity, cardiac disease, and type‑2 diabetes cost over $200 billion annually in the United States alone.

Loss of mitochondrial mass is a major driver of decreased metabolic rate and age‑related energy imbalance.

OUR TECHNOLOGY

Bionic Discovery Platform

HIGH THROUGHPUT BIOLOGY

Tissue Dynamics' advanced robotic automation platform allows for the formation, tracking, and long-term study of over 20,000 human organoids in parallel. The system eliminates human error and drastically reduces technical variability. 

Product rendering of a machine that looks like a black shiny rectangular box in front of a dark gray background. The top and right sides of the machine are visible. On its front and to the left, the machine features a vertical screen displaying colorful squares and status indicators. To its right, there is a closed flap. On the lower right corner of the machine’s front, there is a logo. It reads “DynamiX” in a large white font, and below it in much smaller letters it reads “Tissue Flux Analyzer”. The right side features two sunken handles, one above the other. At the very top of the right side, there is a LED lamp shining green light.

ADVANCED SENSOR TECHNOLOGY

The DynamiX platform enables the real-time readout of human organoid metabolism and function under physiological conditions, providing critical insight into the dynamics and mechanism of disease.  

High resolution image of an organoid under a microscope. The organoid is visible in spots that are colored bright pink and green, creating contrast with the black background.

DISCOVERY & GENERATION

The MechaniX software suite reconstructs metabolic networks and process dynamics to identify novel targets, generate unique assets, and predict human-relevant toxicity with over 95% accuracy.

tissue_dynamics_israel_cover.jfif

Disruptive Drug Development

FIRST IN CLASS THERAPEUTICS
UNRAVELING THE MECHANISMS OF DISEASE

enhanced_edited.jpg

OUR ASSETS

In development

PROGRAM
TARGET
INDICATION
STAGE OF DEVELOPMENT
PARTNER

​TD02-OVL5

UBL5

Obesity/CBD

Preclin

IND

Phase I

Phase II

Phase III

TD07-AFC2

SCD-1 & PPARA

Cardiac Fibrosis

Preclin

IND

Phase I

Phase II

Phase III

TD06-MMT6

AMPK

Arrhythmia

Preclin

IND

Phase I

Phase II

Phase III

TD30-EVO2

BTK & PPARG

Multiple Sclerosis

Preclin

IND

Phase I

Phase II

Phase III

STAGE OF DEVELOPMENT

Preclin

IND

Phase I

Phase II

Phase III

TARGET

UBL5

PARTNER
PROGRAM

​TD02-OVL5

INDICATION

Obesity/CBD

STAGE OF DEVELOPMENT

Preclin

IND

Phase I

Phase II

Phase III

TARGET

SCD-1 & PPARA

PARTNER
PROGRAM

TD07-AFC2

INDICATION

Cardiac Fibrosis

STAGE OF DEVELOPMENT

Preclin

IND

Phase I

Phase II

Phase III

TARGET

AMPK

PARTNER
PROGRAM

TD06-MMT6

INDICATION

Arrhythmia

STAGE OF DEVELOPMENT

Preclin

IND

Phase I

Phase II

Phase III

TARGET

BTK & PPARG

PARTNER
PROGRAM

TD30-EVO2

INDICATION

Multiple Sclerosis

OUR TEAM

We are led by top professionals

kobi.png

YAAKOV NAHMIAS

Professor; Founder

nobel.png

ROGER D. KORNBERG

Professor; Nobel laureate, Stanford

erez.png

EREZ VIGODMAN

Former CEO of TEVA

avner1.png

AVNER EHRLICH

PhD; CTO

raymond.png

RAYMOND CYPESS

Professor; Chairman, ATCC

ariela.png

ARIELA MARKEL

VP Healthcare Yissum

OUR PARTNERS

Collaborations and Partnerships

novo.png
bc.png
atcc.png
abbott.png
nvidia.png
merck.png
bottom of page